Document is current
Any future updates will be listed below
-
Authors
Lazaridou, E.
Kourlaba, G.
Lampropoulou, D. I.
Gounelas, G.
Tsolakidis, A.
Mathioudakis, K.
Apalla, Z.
-
Funding
Funding for this research was provided by:
LEO Pharma, Greece
- License Information
-
More Information
Article History
Received: 28 March 2024
Revised: 8 May 2024
Accepted: 13 May 2024
First Online: 7 June 2024
Declarations
:
: EL: Research grant to Aristotle University, Thessaloniki by Leo Pharma for the present study. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, participation on a Data Safety Monitoring Board or Advisory Board, and support for attending meetings and/or travel from Abbvie, Novartis, Pfizer, UCB, Lilly, Sanofi, Genesis Pharma, Amgen, Janssen, Galderma, Galenica, Leo Pharma. GK: Payments from Aristotle University, Thessaloniki for this work. Contract with Pfizer via University of the Peloponnese for therapeutic area other than psoriasis. Contracts with UCB, Abbvie, Leo, BMS via consulting firm. DIL: None. GG: employee of ECONCARE LP which had contracts with UCB, Abbvie, Leo, BMS. AT: None. KM: None. ZA: Honoraria for lectures and for travels from Abbvie, Sanofi, Pfizer, Leo, Janssen, UCB.
